RT Journal Article
T1 Contribution of cardio-vascular risk factors to depressive status in the PREDIMED-PLUS Trial. A cross-sectional and a 2-year longitudinal study
A1 Martín-Peláez, Sandra
A1 Serra-Majem, Lluis
A1 Cano-Ibáñez, Naomi
A1 Martínez-González, Miguel Ángel
A1 Salas-Salvadó, Jordi
A1 Corella, Dolores
A1 Lassale, Camille
A1 Martínez, Jose Ángel
A1 Alonso-Gómez, Ándres M
A1 Warnberg, Julia
A1 Vioque, Jesús
A1 Romaguera, Dora
A1 López-Miranda, José
A1 Estruch, Ramon
A1 Tinahones, Francisco
A1 Lapreta, José
A1 Fernández-Aranda, Fernando
A1 Bueno-Cavanillas, Aurora
A1 Tur, Josep
A1 Martin, Vicente
A1 Pintó, Xavier
A1 Delgado-Rodríguez, Miguel
A1 Matia, Pilar
A1 Vidal, Josep
A1 Vazquez, Clotilde
A1 Daimiel, Lidia
A1 Ros, Emili
A1 Toledo, Estefanía
A1 Nishi, Stephanie
A1 Sorli, Jose
A1 Malcampo, Mireia
A1 Zulet, M. Ángeles
A1 Moreno-Rodríguez, Anai
A1 Cueto-Galán, Raquel
A1 Vivancos-Aparicio, Diego
A1 Colom, Antoni
A1 García-Ríos, Antonio
A1 Casas, Rosa
A1 Bernal-López, M. Rosa
A1 Santos-Lozano, Jose Manuel
A1 Vázquez, Zenaida
A1 Gómez-Martínez, Carlos
A1 Ortega-Azorín, Carolina
A1 Del Val, Jose Luis
A1 Abete, Itziar
A1 Goikoetxea-Bahon, Amaia
A1 Pascual, Elena
A1 Becerra-Tomás, Nerea
A1 Chillarón, Juan
A1 Sánchez-Villegas, Almudena
K1 Depresión
K1 Corazón - Enfermedades
AB Background: Cardio-vascular disease and depression are thought to be closely related, due to shared risk factors. The aim of the study was to determine the association between cardio-vascular risk (CVR) factors and depressive status in a population (55–75 years) with metabolic syndrome (MetS) from the PREDIMED-Plus trial. Methods and findings: Participants were classified into three groups of CVR according to the Framingham-based REGICOR function: (1) low (LR), (2) medium (MR) or (3) high/very high (HR). The Beck Depression Inventory-II (BDI-II) was used to assess depressive symptoms at baseline and after 2 years. The association between CVR and depressive status at baseline (n = 6545), and their changes after 2 years (n = 4566) were evaluated through multivariable regression models (logistic and linear models). HR women showed higher odds of depressive status than LR [OR (95% CI) = 1.78 (1.26, 2.50)]. MR and HR participants with total cholesterol <160 mg/mL showed higher odds of depression than LR [OR (95% CI) = 1.77 (1.13, 2.77) and 2.83 (1.25, 6.42) respectively)] but those with total cholesterol ≥280 mg/mL showed lower odds of depression than LR [OR (95% CI) = 0.26 (0.07, 0.98) and 0.23 (0.05, 0.95), respectively]. All participants decreased their BDI-II score after 2 years, being the decrease smaller in MR and HR diabetic compared to LR [adjusted mean±SE = -0.52±0.20, -0.41±0.27 and -1.25±0.31 respectively). MR and HR participants with total cholesterol between 240–279 mg/mL showed greater decreases in the BDI-II score compared to LR (adjusted mean±SE = -0.83±0.37, -0.77±0.64 and 0.97±0.52 respectively). Conclusions: Improving cardiovascular health could prevent the onset of depression in the elderly. Diabetes and total cholesterol in individuals at high CVR, may play a specific role in the precise response. International Standard Randomized Controlled Trial (ISRCTN89898870).
PB PLOS ONE
SN 1932-6203
YR 2022
FD 2022-04-13
LK https://hdl.handle.net/10630/45354
UL https://hdl.handle.net/10630/45354
LA eng
NO Martín-Peláez S, Serra-Majem L, Cano-Ibáñez N, Martínez-González MÁ, Salas-Salvadó J, Corella D, Lassale C, Martínez JA, Alonso-Gómez ÁM, Wärnberg J, Vioque J, Romaguera D, López-Miranda J, Estruch R, Tinahones FJ, Lapetra J, Fernández-Aranda F, Bueno-Cavanillas A, Tur JA, Martín V, Pintó X, Delgado-Rodríguez M, Matía P, Vidal J, Vázquez C, Daimiel L, Ros E, Toledo E, Nishi SK, Sorli JV, Malcampo M, Zulet MÁ, Moreno-Rodríguez A, Cueto-Galán R, Vivancos-Aparicio D, Colom A, García-Ríos A, Casas R, Bernal-López MR, Santos-Lozano JM, Vázquez Z, Gómez-Martínez C, Ortega-Azorín C, Del Val JL, Abete I, Goikoetxea-Bahon A, Pascual E, Becerra-Tomás N, Chillarón JJ, Sánchez-Villegas A. Contribution of cardio-vascular risk factors to depressive status in the PREDIMED-PLUS Trial. A cross-sectional and a 2-year longitudinal study. PLoS One. 2022 Apr 13;17(4):e0265079. doi: 10.1371/journal.pone.0265079. PMID: 35417452; PMCID: PMC9007355.
NO International Standard Randomized Controlled Trial (ISRCTN89898870)
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 28 feb 2026